A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression.
Matrix metalloproteases (MMPs) are zinc endopeptidases deeply implicated in tumor progression. MMP inhibitors are attractive potential anti-cancer agent. Unfortunately, until now, clinical trials remain disappointing, that could be the result of a lack of selectivity. We propose second generation selective MMPs, directed toward gelatinase A (MMP-2), based on a non-hydroxamate Zn-ligand grafted on the galardin (ilomastat) skeleton.